Pharmaceutical composition containing KW-6002 and fluoxetine or paroxentine
View Patent ↗The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A 2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HT 2 antagonist or the like), and the like.
1. A method for treating depression, which comprises administering
(a) (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione represented by formula (I):
or a pharmaceutically acceptable salt thereof; and
(b) an antidepressant drug selected from the group consisting of fluoxetine and paroxetine, or pharmaceutically acceptable salts thereof, simultaneously or separately at a time interval.
2. The method according to claim 1 , wherein said pharmaceutically acceptable salt of fluoxetine or paroxetine is a hydrochloride.
3. The method according to claim 2 , wherein the antidepressant drug is paroxetine hydrochloride and said paroxetine hydrochloride is paroxetine hydrochloride hydrate.
4. The method according to claim 2 , wherein said (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione and said fluoxetine hydrochloride or paroxetine hydrochloride are administered simultaneously.
5. The method according to claim 2 , wherein said (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione and said fluoxetine hydrochloride or paroxetine hydrochloride are administered at a time interval of from 30 minutes to 30 hours.
6. A method for treating depression, which comprises administering
(a) (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione represented by formula (I):
or a pharmaceutically acceptable salt thereof; and
(b) fluoxetine or a pharmaceutically acceptable salt thereof, simultaneously or separately at a time interval.
7. The method according to claim 6 , wherein said pharmaceutically acceptable salt of fluoxetine is a hydrochloride.
8. The method according to claim 7 , wherein said (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione and said fluoxetine hydrochloride are administered simultaneously.
9. The method according to claim 7 , wherein said (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione and said fluoxetine hydrochloride are administered at a time interval of from 30 minutes to 30 hours.
10. A method for treating depression, which comprises administering
(a) (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione represented by formula (I):
or a pharmaceutically acceptable salt thereof; and
(b) paroxetine or a pharmaceutically acceptable salt thereof, simultaneously or separately at a time interval.
11. The method according to claim 10 , wherein said pharmaceutically acceptable salt of paroxetine is a hydrochloride.
12. The method according to claim 11 , wherein said paroxetine hydrochloride is paroxetine hydrochloride hydrate.
13. The method according to claim 11 , wherein said (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione and said paroxetine hydrochloride are administered simultaneously.
14. The method according to claim 11 , wherein said (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione and said paroxetine hydrochloride are administered at a time interval of from 30 minutes to 30 hours.